| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14712598.2011.548798 |
| P698 | PubMed publication ID | 21299437 |
| P50 | author | Filip Eftimov | Q91890454 |
| Ivo N van Schaik | Q91890462 | ||
| P2860 | cites work | European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy | Q33252355 |
| Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures | Q33340214 | ||
| Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project | Q33383576 | ||
| Adverse effects of intravenous immunoglobulin therapy | Q33733019 | ||
| Multifocal motor neuropathy with conduction block: a study of 24 patients | Q33734400 | ||
| Long term follow up of multifocal motor neuropathy with conduction block under treatment | Q33735714 | ||
| Multifocal motor neuropathy: response to human immune globulin | Q34062007 | ||
| Multifocal motor neuropathy. | Q34204618 | ||
| Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin | Q34362734 | ||
| Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids | Q34381920 | ||
| Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies | Q34620111 | ||
| Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. | Q34950507 | ||
| Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies | Q35033520 | ||
| Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies | Q35449950 | ||
| Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. | Q35467947 | ||
| Axon loss is an important determinant of weakness in multifocal motor neuropathy | Q36142106 | ||
| Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy | Q36317538 | ||
| Intravenous immunoglobulin and dendritic cells. | Q36359678 | ||
| Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study | Q36880697 | ||
| The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. | Q37111379 | ||
| Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy | Q37443488 | ||
| Beneficial effect of rituximab monotherapy in multifocal motor neuropathy | Q37495029 | ||
| Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study | Q40011079 | ||
| Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study | Q40444373 | ||
| Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors | Q40697360 | ||
| Motor conduction block and high titres of anti-GM1 ganglioside antibodies: pathological evidence of a motor neuropathy in a patient with lower motor neuron syndrome. | Q41387060 | ||
| Immunomodulation and remyelination: two aspects of human polyclonal immunoglobulin treatment in immune mediated neuropathies? | Q41589704 | ||
| In vitro effects of polyvalent immunoglobulin for intravenous use. | Q41663188 | ||
| Bilateral phrenic neuropathy as a presenting feature of multifocal motor neuropathy with conduction block | Q41724865 | ||
| Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin | Q41766911 | ||
| An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy | Q42840212 | ||
| Treatment of IgM antibody associated polyneuropathies using rituximab | Q43069450 | ||
| Plasmapheresis in multifocal motor neuropathy: a case report | Q43071840 | ||
| Case-control study of thromboembolic events associated with IV immunoglobulin | Q43422324 | ||
| Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease | Q43839016 | ||
| Mycophenolate in treatment-resistant inflammatory neuropathies | Q44230238 | ||
| IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy | Q44587933 | ||
| Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. | Q44873430 | ||
| A syndrome of asymmetric limb weakness with motor conduction block | Q44992268 | ||
| High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study | Q45361840 | ||
| Multifocal motor neuropathy with conduction block misdiagnosed as multiple entrapment neuropathies | Q46163603 | ||
| Therapeutic apheresis in Sweden: update of epidemiology and adverse events. | Q47663656 | ||
| IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up | Q48006982 | ||
| Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial | Q48107965 | ||
| Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro | Q48194734 | ||
| Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment | Q48536321 | ||
| Subcutaneous immunoglobulin therapy for multifocal motor neuropathy | Q49074281 | ||
| Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study | Q49125609 | ||
| How long is IVIg effective in multifocal motor neuropathy? | Q51021985 | ||
| Acute conduction block in vitro following exposure to antiganglioside sera. | Q51662994 | ||
| A case of spontaneously recovering multifocal motor neuropathy with conduction blocks (MMNCB) during anti-TNF alpha therapy for ankylosing spondylitis. | Q51731874 | ||
| Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. | Q51936602 | ||
| High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. | Q53771496 | ||
| Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. | Q53901414 | ||
| Motor Neuropathy with Proximal Multifocal Persistent Conduction Block, Fasciculations and Myokymia | Q56608957 | ||
| Multifocal motor neuropathy with and without conduction block: A single entity? | Q59243994 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 329-342 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Immunotherapy of multifocal motor neuropathy | |
| P478 | volume | 11 |
| Q42654125 | A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy |
| Q38824175 | Diagnostic Biopsy of a Motor Branch of the Superficial Peroneal Nerve to the Peroneus Longus: A Convenient Alternative for Motor Nerve Biopsy |
| Q38039965 | Immune pathogenesis and treatment of multifocal motor neuropathy |
| Q37959252 | Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies |
| Q35537340 | The pathogenesis of multifocal motor neuropathy and an update on current management options |
| Q38202020 | Treatment of multifocal motor neuropathy with intravenous immunoglobulin |
Search more.